Ewing's sarcoma precursors are highly enriched in embryonic osteochondrogenic progenitors

Journal of Clinical Investigation

Volumn 124, Issue 7, 2014, Pages 3061-3074

  Tanaka, Miwa ^a   Yamazaki, Yukari ^a   Kanno, Yohei ^a   Igarashi, Katsuhide ^b   Aisaki, Ken Ichi ^b   Kanno, Jun ^b   Nakamura, Takuro ^a  

^a CANCER INSTITUTE   (Japan)

^b NATIONAL INSTITUTE OF HEALTH SCIENCES   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; GROWTH DIFFERENTIATION FACTOR 5; HYBRID PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; PARATHYROID HORMONE; PARATHYROID HORMONE LIKE HORMONE; RNA BINDING PROTEIN EWS; RNA BINDING PROTEIN EWS TRANSCRIPTION FACTOR ETS FUSION PROTEIN; TRANSCRIPTION FACTOR ERG; TRANSCRIPTION FACTOR ETS; TRANSCRIPTION FACTOR EZH2; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL GROWTH; CHROMATIN STRUCTURE; CONTROLLED STUDY; DISEASE COURSE; EMBRYO; EWING SARCOMA; GENE EXPRESSION; HISTOGENESIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; STEM CELL;

ANIMALS; BETA CATENIN; BONE NEOPLASMS; CHONDROCYTES; DISEASE MODELS, ANIMAL; EMBRYONIC STEM CELLS; FEMALE; GENE EXPRESSION PROFILING; GENE FUSION; HUMANS; MICE; MICE, INBRED BALB C; NEOPLASTIC STEM CELLS; OSTEOBLASTS; PREGNANCY; PROTO-ONCOGENE PROTEINS C-ETS; RNA-BINDING PROTEIN EWS; SARCOMA, EWING; WNT SIGNALING PATHWAY;

EID: 84903786142     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI72399     Document Type: Article

References (71)

1. Bernstein M, et al. Ewing?s sarcoma family of tumors: current management. Oncologist. 2006;11(5):503-519.
2. Ewing J. Diffuse endothelioma of bone. Proc New York Pathol Soc. 1921;21:17-24.
3. Hu-Lieskovan S, Zhang J, Wu L, Shimada H, Schofield DE, Triche TJ. EWS-FLI1 fusion protein up-regulates critical genes in neural crest development and is responsible for the observed phenotype of Ewing?s family of tumors. Cancer Res. 2005;65(11):4633-4644.
4. Tirode F, Laud-Duval K, Prieur A, Delorme B, Cahrbord P, Delattre O. Mesenchymal stem cell features of Ewing tumors. Cancer Cell. 2007;11(5):421-429.
5. Delattre O, et al. Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours. Nature. 1992;359(6391):162-165.
6. Zucman J, et al. Combinatorial generation of variable fusion proteins in the Ewing family of tumours. EMBO J. 1993;12(12):4481-4487.
7. Sorensen PH, Lessnick SL, Lopez-Terrada D, Liu XF, Triche TJ, Denny CT. A second Ewing?s sarcoma translocation, t(21;22), fuses the EWS gene to another ETS-family transcription factor, ERG. Nat Genet. 1994;6(2):146-151.
8. Ordonez JL, Osuna D, Herrero D, de Alava E, Madoz-Gurpide J. Advances in Ewing?s sarcoma research: where are we now and what lies ahead? Cancer Res. 2009;69(18):7140-7150.
9. Riggi N, et al. Development of Ewing?s sarcoma from primary bone marrow-derived mesenchymal progenitor cells. Cancer Res. 2005;65(24):11459- 11468.
10. Castillero-Trejo Y, Eliazer S, Xiang L, Richardson JA, Ilaria RL Jr. Expression of the EWS/FLI-1 oncogene in murine primary bone-derived cells results in EWS/FLI-1-dependent, Ewing sarcoma-like tumors. Cancer Res. 2005;65(19):8698-8705.
11. Arndt CAS, Crist WM. Common musculoskeletal tumors of childhood and adolescence. N Engl J Med. 1999;341(5):342-352.
12. Iwamoto M, et al. 2007. Transcription factor ERG and joint and articular cartilage formation during mouse limb and spine skeletogenesis. Dev Biol. 2007;305(1):40-51.
13. Koyama E, et al. A distinct cohort of progenitor cells participates in synovial joint and articular cartilage formation during mouse limb skeletogenesis. Dev Biol. 2008;316(1):62-73.
14. Mundy C, et al. Synovial joint formation requires local Ext1 expression and heparin sulfate production in developing mouse embryo limbs and spine. Dev Biol. 2011;351(1):70-81.
15. Ambros IM, Ambros PF, Strehl S, Kovar H, Gadner H, Salzer-Kuntschik M. MIC2 is a specific marker for Ewing?s sarcoma and peripheral primitive neuroectodermal tumors. Evidence for a common histogenesis of Ewing?s sarcoma and peripheral primitive neuroectodermal tumors from MIC2 expression and specific chromosome aberration. Cancer. 1991;67(7):1886-1893.
16. Bixel G, Kloep S, Butz S, Petri B, Engelhardt B, Vestweber D. Mouse CD99 participates in T-cell recruitment into inflamed skin. Blood. 2004;104(10):3205-3213.
17. Vortkamp A, Lee K, Lanske B, Segre GV, Kronenberg HM, Tabin CJ. Regulation of rate of cartilage differentiation by Indian Hedgehog and PTH-related protein. Science. 1996;273(5275):613-622.
18. Sohaskey ML, Yu J, Diaz MA, Plaas AH, Harland RM. JAWS coordinates chondrogenesis and synovial joint positioning. Development. 2008;135(13):2215- 2220.
19. Vijayaraj P, et al. Erg is a crucial regulator of endocardial-mesenchymal transformation during cardiac valve morphogenesis. Development. 2012; 139(21):3973-3985.
20. Storm EE, Kingsley DM. GDF5 coordinates bone and joint formation during digit development. Dev Biol. 1999;209(1):11-27.
21. St-Jacques B, Hammerschmidt M, McMahon AP. Indian hedgehog signaling regulates proliferation and differentiation of chondrocytes and is essential for bone formation. Genes Dev. 1999;13(16):2072-2086.
22. Mak KK, Kronenberg HM, Chuang PT, Mackem S, Yang Y. Indian hedgehog signals independently of PTHrP to promote chondrocyte hypertrophy. Development. 2008;135(11):1947-1956.
23. Toomey EC, Schiffman JD, Lessnick SL. Recent advances in the molecular pathogenesis of Ewing?s sarcoma. Oncogene. 2010;29(32):4504-4516.
24. James CG, Stanton LA, Agoston H, Ulici V, Underhill TM, Beier F. Genome-wide analyses of gene expression during mouse endochondral ossification. PLoS One. 2010;5(1):e8693.
25. Honsei N, Ikuta T, Kawana K, Kaneko Y, Kawajiri K. Participation of nuclear localization signal 2 in the 3′-ETS domain of FLI1 in nuclear translocation of various chimeric EWS-FLI1 oncoproteins in Ewing tumor. Int J Oncol. 2006;29(3):689-693.
26. Miyagawa Y, et al. EWS/ETS regulates the expression of the Dickkopf family in Ewing family tumor cells. PLoS One. 2009;4(2):e4634.
27. Surdez D, et al. Targeting the EWSR1-FLI1 oncogene-induced protein kinase PKC-αabolishesβ Ewing sarcoma growth. Cancer Res. 2012;72(17):4494-4503.
28. Richter GH, et al. EZH2 is a mediator of EWS/FLI1 driven tumor growth and metastasis blocking endothelial and neuro-ectodermal differentiation. Proc Natl Acad Sci U S A. 2009;106(13):5324-5329.
29. Nishimori H, et al. The Id2 gene is a novel target of transcriptional activation by EWS-ETS fusion proteins in Ewing family tumors. Oncogene. 2002;21(54):8302-8309.
30. Smith R, et al. Expression profiling of EWS/ FLI1 identifies NKX2.2 as a critical target gene in Ewing?s sarcoma. Cancer Cell. 2006;9(5):405-416.
31. Kinsey M, Smith R, Lessnick SL. NR0B1 is required for the oncogenic phenotype mediated by EWS/FLI in Ewing?s sarcoma. Mol Cancer Res. 2006;4(11):851-859.
32. Abaan OD, Levenson A, Khan O, Furth PA, Uren A, Toretsky JA. PTPL1 is a direct transcriptional target of EWS-FLI1 and modulates Ewing?s sarcoma tumorigenesis. Oncogene. 2005;24(16):2715-2722.
33. Wakahara K, et al. EWS-Fli1 up-regulates expression of the Aurora A and Aurora B kinases. Mol Cancer Res. 2008;6(12):1937-1945.
34. Luo W, Gangwal K, Sankar S, Boucher KM, Thomas D, Lessnick SL. GSTM4 is a microsatellite-containing EWS/FLI target involved in Ewing?s sarcoma oncogenesis and therapeutic resistance. Oncogene. 2009;28(46):4126-4132.
35. Fuchs B, Inwards C, Scully SP, Janknecht R. hTERT is highly expressed in Ewing?s sarcoma and activated by EWS-ETS oncoproteins. Clin Orthop Relat Res. 2004;426(426):64-68.
36. Watanabe G, et al. Induction of tenascin-C by tumor-specific EWS-ETS fusion genes. Genes Chromosomes Cancer. 2003;36(3):224-232.
37. Deneen B, Hamidi H, Denny CT. Functional analysis of the EWS/ETS target gene uridine phosphorylase. Cancer Res. 2003;63(14):4268-4274.
38. Hahm KB, et al. Repression of the gene encoding the TGF-beta type II receptor is a major target of the EWS-FLI1 oncoprotein. Nat Genet. 1999; 23(2):222-227.
39. Dohjima T, Ohno T, Banno Y, Nozawa Y, Wen-yi Y, Shimizu K. Preferential down-regulation of phospholipase C-beta in Ewing?s sarcoma cells transfected with antisense EWS-Fli-1. Br J Cancer. 2000;82(1):16-19.
40. Scotlandi K, et al. Insulin-like growth factor I receptor-mediated circuit in Ewing?s sarcoma/peripheral neuroectodermal tumor: a possible therapeutic target. Cancer Res. 1998;56(20):4570-4574.
41. Balamuth NJ, Womer RB. Ewing?s sarcoma. Lancet Oncol. 2010;11(2):184-192.
42. Niehrs C. Function and biological roles of the Dickkopf family of Wnt modulators. Oncogene. 2006;25(57):7469-7481.
43. Mikheev AM, Mikheeva SA, Liu B, Cohen P, Zarbl H. A functional genomics approach for the identification of putative tumor suppressor genes: Dickkopf-1 as suppressor of HeLa cell transformation. Carcinogenesis. 2004;25(1):47-59.
44. Uren A, Wolf V, Sun YF, Azari A, Rubin JS, Toretsky JA. Wnt/Frizzled signaling in Ewing sarcoma. Pediatr Blood Cancer. 2004;43(3):243-249.
45. Garnett MJ, et al. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature. 2012;483(7391):570-575.
46. Deneen B, Denny CT. Loss of p16 pathways stabilizes EWS/FLI1 expression and complements EWS/FLI1 mediated transformation. Oncogene. 2001;20(46):6731- 6741.
47. Sohn EJ, Li H, Reldy K, Beers LF, Christensen BL, Lee SB. EWS/FLI1 oncogene activates caspase 3 transcription and triggers apoptosis in vivo. Cancer Res. 2010;70(3):1154-1163.
48. Riggi N, et al. EWS-FLI-1 modulates miRNA145 and SOX2 expression to initiate mesenchymal stem cell reprogramming toward Ewing sarcoma cancer stem cells. Genes Dev. 2010;24(9):916-932.
49. Grier HE. The Ewing family of tumors: Ewing?s sarcoma and primitive neuroectodermal tumors. Pediatr Clin North Am. 1997;44(4):991-1004.
50. Soliman H, Ferrari A, Thomas D. Sarcoma in the young adult population: An international view. Sem Oncol. 2009;36(3):227-236.
51. Martins AS, et al. A pivotal role for heat shock protein 90 in Ewing sarcoma resistance to anti-insulinlike growth factor 1 receptor treatment: in vitro and in vivo study. Cancer Res. 2008;68(15):6260-6270.
52. Glade Bender JL, et al. Phase I pharmacokinetic and pharmacodynamics study of pazopanib in children with soft tissue sarcoma and other refractory solid tumors: a children?s oncology group phase I consortium report. J Clin Oncol. 2013;31(24):3034-3043.
53. Jin G, et al. Trib1 and Evi1 cooperate with Hoxa and Meis1 in myeloid leukemogenesis. Blood. 2007;109(9):3998-4005.
54. Kawamura-Saito M, et al. Fusion between CIC and DUX4 up-regulates PEA3 family genes in Ewinglike sarcomas with t(4;19)(q35;q13) translocation. Hum Mol Genet. 2006;15(13):2125-2137.
55. Pittenger MF, et al. Multilineage potential of adult human mesenchymal stem cells. Science. 1999;284(5411):143-147.
56. Sakaguchi Y, Sekiya I, Yagishita K, Muneta T. Comparison of human stem cells derived from various mesenchymal tissues: superiority of synovium as a cell source. Arthritis Rheum. 2005;52(8):2521-2529.
57. Shiota M, et al. Isolation and characterization of bone marrow-derived mesenchymal progenitor cells with myogenic and neuronal properties. Exp Cell Res. 2007;313(5):1008-1023.
58. Kanno J, et al. "Per cell" normalization method for mRNA measurement by quantitative PCR and microarrays. BMC Genomics. 2006;7:64.
59. Fujino T, et al. Function of EWS-POU5F1 in sarcomagenesis and tumor cell maintenance. Am J Pathol. 2010;176(4):1973-1982.
60. Subramanian A, Kuehn H, Gould J, Tamayo P, Mesirov JP. GSEA-P: a desktop application for gene set enrichment analysis. Bioinformatics. 2007; 23(23):3251-3253.
61. Henderson SR, et al. A molecular map of mesenchymal tumors. Genome Biol. 2005;6(9):R76.
62. Schaefer KL, et al. Microarray analysis of Ewing?s sarcoma family of tumours reveals characteristic gene expression signatures associated with metastasis and resistance to chemotherapy. Eur J Cancer. 2008;44(5):699-709.
63. Nakayama R, et al. Gene expression analysis of soft tissue sarcomas: characterization and reclassification of malignant fibrous histiocytoma. Mod Pathol. 2007;20(7):749-759.
64. Albino D, et al. Identification of low intratumoral gene expression heterogeneity in neuroblastic tumors by genome-wide expression analysis and game theory. Cancer. 2008;113(6):1412-1422.
65. Barretina J, et al. Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. Nat Genet. 2010;42(8):715-721.
66. Haldar M, et al. A conditional mouse model of synovial sarcoma: insights into a myogenic origin. Cancer Cell. 2007;11(4):375-388.
67. Teitz T. et al. Th-MYCN mice with caspase-8 deficiency develop advanced neuroblastoma with bone marrow metastasis. Cancer Res. 2013;73(13):4086-4097.
68. Jeannet R, et al. Oncogenic activation of the Notch1 gene by deletion of its promoter in Ikaros-deficient T-ALL. Blood. 2010;115(25):5443-5454.
69. Nakayama R, et al. Gene expression profiling of synovial sarcoma: distinct signature of poorly differentiated type. Am J Surg Pathol. 2010;34(11):1599-1607.
70. Masque-Soler N, Szczepanowski M, Kohler CW, Spang R, Klapper W. Molecular classification of mature aggressive B-cell lymphoma using digital multiplexed gene expression on formalin-fixed paraffin-embedded biopsy specimens. Blood. 2013; 122(11):1985-1986.
71. Tanaka M, Jin G, Yamazaki Y, Takahara T, Takuwa M, Nakamura T. Identification of candidate cooperative genes of the Apc mutation in transformation of the colon epithelial cell by retroviral insertional mutagenesis. Cancer Sci. 2008;99(5):979-985.